Application of a CXCL12/CXCR4 inhibitor (a) remodels and promotes release of adhesive tumor cells from the protective microenvironment making them more susceptible to conventional therapy and (b) improves the tumor infiltration and activation of cytotoxic T-lymphocytes in immune checkpoint blockade therapy [10]. Here, CXCL12 is linked to neoplasm.